Has Daniel Arnoldi received payments from drug or device companies?

Yes. Drug and device makers reported $3,070 in general payments to Daniel Arnoldi across 103 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Daniel Arnoldi did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Daniel Arnoldi come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Daniel Arnoldi

Optometrist · Staten Island, NYNPI 1184726291

Payments from drug & device makers

$3,070in general payments, 2019–2025

Across 103 payments — averaging $29.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sight Sciences, Inc.$837
Heru, Inc.$452
Alcon$320
Novartis$248
Sun Pharmaceutical Industries Inc.$190
Harrow Eye, LLC$151
plus $871 from 17 others

What the payments were for

Food & beverage$3,070100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sight Sciences, Inc.	11	$837
Heru, Inc.	2	$452
Alcon	9	$320
Novartis	17	$248
Sun Pharmaceutical Industries Inc.	13	$190
Harrow Eye, LLC	7	$151
Bausch & Lomb Americas Inc.	8	$144
Tarsus Pharmaceuticals, Inc.	5	$113
Oyster Point Pharma, Inc.	7	$101
Rxsight Inc	1	$94
Ivantis, Inc	1	$71
AbbVie	4	$58
Bausch & Lomb, A Division Of Bausch Health US, LLC	3	$41
Thea Pharma Inc.	2	$36
Mallinckrodt Hospital Products Inc.	2	$33
Alimera Sciences, Inc.	2	$31
Aerie Pharmaceuticals, Inc.	2	$29
Dompe US, Inc.	2	$29
ANI Pharmaceuticals, Inc.	1	$25
Maculogix, Inc.	1	$20
Amgen	1	$17
Eyevance Pharmaceuticals LLC	1	$16
Shire North American Group Inc	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,070 in reported general payments places this provider in the 85th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Cyclosporine	18	$10,910
LumiganBimatoprost	19	$10,435
Travoprost	19	$4,772
Brimonidine Tartrate	21	$4,475
Alphagan PBrimonidine Tartrate	14	$3,688
Tobramycin-DexamethasoneTobramycin/Dexamethasone	118	$3,028
TobradexTobramycin/Dexamethasone	11	$2,802
Latanoprost	282	$2,757
Prednisolone Acetate	44	$1,715
Timolol Maleate	45	$1,681
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	74	$1,471
Azelastine Hcl	56	$1,058
Dorzolamide Hcl	21	$285
Ketorolac Tromethamine	19	$251
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	13	$123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieLumigan, Alphagan P	$58	$14,12333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,743 optometrist providers in New York.

Other optometrist in Staten Island

Andrew SaccoVestal$1.8M
George ZikosNew York$1M
Roy KlineLake Katrine$822K
Irene FrantzisNew York$663K
Daphne AmbroseNew York$509K
Susan ResnickNew York$463K
Murray FingeretHewlett$384K
Albert MorierSlingerlands$347K
Denise WhittamNew York$343K
Justin BazanBrooklyn$304K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →